PNH
Novartis Reveals Sustained Efficacy and Safety of Fabhalta in Patients Switching from Anti-C5 Therapies for Paroxysmal Nocturnal Hemoglobinuria (PNH)
Fabhalta (iptacopan), Paroxysmal Nocturnal Hemoglobinuria (PNH), Anti-C5 therapies, Efficacy and safety, Switching therapies, Hemoglobin improvement, Transfusion avoidance
Roche’s PiaSky Receives European Approval for Rare Blood Disorder Treatment
Roche, PiaSky, Crovalimab, Paroxysmal Nocturnal Hemoglobinuria (PNH), Rare Blood Disorder, European Approval
FDA Approves Amgen’s Bkemv, First Interchangeable Biosimilar to Soliris for Rare Blood Disorders ###
Bkemv, Soliris, FDA approval, Interchangeable biosimilar, Rare blood disorders, Paroxysmal nocturnal hemoglobinuria (PNH), Atypical hemolytic uremic syndrome (aHUS), Amgen, AstraZeneca, Alexion Pharmaceuticals
Amgen Secures FDA Approval for Bkemv, the First Interchangeable Biosimilar to Soliris for Rare Blood Disorders
FDA approval, Amgen, Bkemv, Soliris, biosimilar, rare blood disorders, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS)